High Vista Strategies LLC Bei Gene, Ltd. Transaction History

High Vista Strategies LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$121.11 - $216.05 $242,462 - $432,532	-2,002 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$146.52 - $269.56 $84,688 - $155,805	-578 Reduced 22.4%	2,002 $378,000
Q4 2021 Feb 14, 2022	SELL	$248.56 - $389.34 $489,414 - $766,610	-1,969 Reduced 43.28%	2,580 $699,000
Q3 2021 Nov 15, 2021	BUY	$249.6 - $403.14 $578,572 - $934,478	2,318 Added 103.9%	4,549 $1.65 Million
Q1 2021 May 17, 2021	BUY	$260.64 - $382.12 $581,487 - $852,509	2,231 New	2,231 $777,000

252

45.3M

292K

119K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $18.6B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of High Vista Strategies LLC, based on Form 13F filings with the SEC.

Stay updated on High Vista Strategies LLC with notifications on news.